Is genetic testing coming of age in advanced prostate cancer?
Corresponding Author
Kenneth Chen
Department of Urology, Singapore General Hospital, Singapore, Singapore
Correspondence: Kenneth Chen, 20 College Road, Academia Level 5, Department of Urology, Singapore General Hospital, Singapore 169856, Singapore.
e-mail: [email protected]
Search for more papers by this authorSean Ong
Royal Melbourne Hospital Clinical School, University of Melbourne, Melbourne, Victoria, Australia
EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia
Search for more papers by this authorKandarpa Vasundhara
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorChow Kit Mun
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorIsabella Williams
Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorRavindran Kanesvaran
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Search for more papers by this authorJohn Yuen Shyi Peng
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorArun A. Azad
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Search for more papers by this authorNathan Lawrentschuk
Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorCorresponding Author
Kenneth Chen
Department of Urology, Singapore General Hospital, Singapore, Singapore
Correspondence: Kenneth Chen, 20 College Road, Academia Level 5, Department of Urology, Singapore General Hospital, Singapore 169856, Singapore.
e-mail: [email protected]
Search for more papers by this authorSean Ong
Royal Melbourne Hospital Clinical School, University of Melbourne, Melbourne, Victoria, Australia
EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia
Search for more papers by this authorKandarpa Vasundhara
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorChow Kit Mun
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorIsabella Williams
Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorRavindran Kanesvaran
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Search for more papers by this authorJohn Yuen Shyi Peng
Department of Urology, Singapore General Hospital, Singapore, Singapore
Search for more papers by this authorArun A. Azad
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Search for more papers by this authorNathan Lawrentschuk
Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author
References
- 1Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 162: 454
- 2Chen K, O'Brien J, McVey A et al. Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? Nat Rev Urol 2023; 20: 116–123
- 3Asim M, Tarish F, Zecchini HI et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun 2017; 8: 374
- 4Clarke NW, Armstrong AJ, Thiery-Vuillemin A et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (Ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2023; 41(6_suppl): LBA16-LBA
10.1200/JCO.2023.41.6_suppl.LBA16 Google Scholar
- 5Chi KN, Rathkopf DE, Smith MR et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol 2022; 40(6_suppl): 12
- 6Rao A, Moka N, Hamstra DA, Ryan CJ. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now? Cancers (Basel) 2022; 14: 801